IDH1 Mutation
10 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms (NCT04955938) | University of Chicago | 2021-10-29 |
| Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors (NCT04056910) | Jason J. Luke, MD | 2021-09-20 |
| BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (NCT03914742) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-02-16 |
Track IDH1 Mutation automatically
Every clearance here is in the API, with alerts when new ones post.